ArticleBiomedical optics express2026
Fiber-optic fluorescence reader for multiplex point-of-care monitoring.
Article in Biomedical optics express, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We present a compact fiber-optic fluorescence reader for quantitative, multiplex point-of-care (PoC) analysis of lateral flow assays (LFAs). The system uses a dual-port fiber Bragg grating (FBG) spectrometer for spectral discrimination and interchangeable excitation sources covering 400-800 nm to support multiple fluorophores. As a proof of principle, we quantified piperacillin in human serum with an europium nanoparticle-based competitive LFA, achieving a limit of detection (LOD) of 12.9 mg/L and a dynamic range of 10-500 mg/L. The reader-LFA system showed strong agreement with a laboratory reference method (Pearson's r = 0.95) and a mean absolute error of 22.9 mg/L across ten patient samples. In addition, we demonstrate multiplex detection of opiate and cocaine markers using distinct fluorophores on a single test line. These results support the feasibility of portable, spectrally resolved PoC diagnostics for therapeutic drug monitoring and multiplex biomarker detection in clinical and low-resource settings.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.